A Phase 2 study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2 Rearranged and/ or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
Contact phone
Neelam Singh, PhD | 517.364.5591
Principal investigator
Dr. Renuka Gera, MD
Trial Category
Childhood Cancers
Trial SubCategory
Leukemia
Webform